Impact Biomedical Secures Patent for Plant-Based Antimicrobial Technology Targeting Infectious Diseases
核心洞察
Impact Biomedical Inc. (搜索) received U.S. patent No. 12,357,584 B2 for its 3F™ technology (搜索) platform, covering compositions and methods for controlling infectious diseases (搜索) using plant-derived fragrances.
The patented technology demonstrates antimicrobial and antiviral properties against various pathogens including E. coli (搜索), MRSA (搜索), influenza (搜索), rhinovirus (搜索), and M. tuberculosis (搜索).
The patent expands IBO's intellectual property portfolio and supports the company's strategy to address unmet needs in the growing infectious disease market, projected to reach $34 billion by 2032.
Impact Biomedical Inc. (搜索) has secured a significant patent for its innovative approach to combating infectious diseases (搜索) through plant-based antimicrobial technology. The U.S. Patent and Trademark Office issued patent No. 12,357,584 B2, entitled "Composition and Method of Controlling Infectious Diseases with Functional Fragrances," marking a key milestone for the company's 3F™ technology (搜索) platform.
Novel Plant-Based Antimicrobial Approach
The patent covers unique compositions and formulations derived from constituents found in plants and their produced fragrances, with potential applications as antibacterial and antiviral agents. These compositions demonstrate antimicrobial and antiviral properties that can be formulated to treat or limit the occurrence of various diseases and serve as disinfectants against microbes and pathogens.
The technology shows potential effectiveness against a broad spectrum of pathogens, including E. coli (搜索), MRSA (搜索), influenza (搜索), rhinovirus (搜索), and M. tuberculosis (搜索). The compositions can be administered to patients for treating infectious disease conditions or used as disinfectants for microbial control.
Expanding Intellectual Property Portfolio
This patent significantly expands Impact Biomedical's 3F™ patent estate, which already includes insect repellent compositions and anti-microbial applications across the United States and other countries. The patent will remain in effect until December 7, 2038, providing the company with long-term intellectual property protection.
"This is another demonstration of success with our business model delivering new unique proprietary technology with the potential to address unmet needs in human healthcare," said Frank Heuszel, CEO of Impact Biomedical. "We continue discussions with potential partners to move 3F™ towards the market in the US and other countries worldwide."
Market Opportunity and Strategic Positioning
The patent comes at a time when infectious diseases (搜索) continue to pose significant global health challenges, driving demand for new solutions in both established and developing regions worldwide. According to market research cited by the company, the worldwide infectious disease market is projected to grow from $21.7 billion in 2024 to $34 billion by 2032, representing a compound annual growth rate of 5.77%.
Impact Biomedical's business model focuses on discovering, confirming, and patenting unique science and technologies that can be developed into new offerings in biopharmaceuticals and consumer healthcare. The company collaborates with external partners through research, licensing, co-development, joint ventures, and other strategic relationships to bring these technologies to market.